Granules India's FY27 Growth Hinges on US FDA Decision, Q4 Outlook Positive

• Granules India's FY25-27 revenue and profit growth depend heavily on the US FDA remediation process outcome, according to Executive Director Priyanka Chigurupati.
• The company anticipates a stronger January-March 2026 quarter due to improved capacity utilization and potential launch of 10-13 pending products post-regulatory clearance.
• Granules India is strategically shifting its product mix towards complex generics, including treatments for ADHD and oncology, to drive long-term growth.
• The company reported a 27.7% year-on-year net profit increase to ₹150.2 crore for the October-December 2025 quarter.
• Fundraising of ₹1,700 crore is aimed at strengthening the balance sheet for potential inorganic opportunities in complex generics, not solely for deleveraging.

Why It Matters: Granules India's future growth, especially in FY27, is critically tied to US FDA approval and complex generics strategy.